Brookline Capital Markets Weighs in on XFOR FY2026 Earnings

Key Points

• Brookline Capital Markets raised its FY2026 EPS estimate for X4 Pharmaceuticals to a loss of $0.69 per share from $0.71, versus the analyst consensus loss of $0.68. It also issued loss estimates of $0.24 for Q4 2026 and $1.00, $1.44, and $0.17 for FY2027–FY2029, respectively.
• X4 reported a quarterly loss of $0.16 per share, beating the $0.17 consensus estimate; revenue of $2.88 million also exceeded expectations of $2.78 million.
• Analyst coverage remains broadly favorable, with a “Moderate Buy” consensus rating and an $11.25 average price target. Shares opened at $3.33, while the stock’s one-year range was $2.43 to $4.83.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Markets boosted their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of ($0.69) for the year, up from their previous estimate of ($0.71). The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.68) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals' Q4 2026 earnings at ($0.24) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($0.17) EPS.

Separately, Weiss Ratings upgraded shares of X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, November 3rd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.25.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock opened at $3.33 on Tuesday. The firm's 50 day moving average price is $3.22 and its 200-day moving average price is $3.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30. X4 Pharmaceuticals has a one year low of $2.43 and a one year high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $2.88 million for the quarter, compared to analyst estimates of $2.78 million. X4 Pharmaceuticals had a negative net margin of 474.74% and a negative return on equity of 47.35%.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Perceptive Advisors LLC lifted its holdings in shares of X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company's stock valued at $27,826,000 after buying an additional 423,196 shares during the period. Russell Investments Group Ltd. raised its position in X4 Pharmaceuticals by 2,871.0% in the third quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company's stock worth $618,000 after acquiring an additional 206,080 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in X4 Pharmaceuticals in the second quarter worth $917,000. Bank of America Corp DE lifted its holdings in X4 Pharmaceuticals by 321.3% in the first quarter. Bank of America Corp DE now owns 150,676 shares of the company's stock valued at $622,000 after acquiring an additional 114,915 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in X4 Pharmaceuticals by 36.2% in the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company's stock valued at $378,000 after acquiring an additional 34,698 shares during the period. Hedge funds and other institutional investors own 72.03% of the company's stock.

Insider Transactions at X4 Pharmaceuticals

In other news, CFO David Kirske sold 11,767 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the sale, the chief financial officer directly owned 155,983 shares of the company's stock, valued at approximately $446,111.38. This represents a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Adam R. Craig sold 47,436 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the sale, the chairman owned 328,651 shares of the company's stock, valued at approximately $1,459,210.44. This represents a 12.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 83,779 shares of company stock worth $353,387. 1.13% of the stock is currently owned by insiders.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company's research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.